Next generation of glyco-immune therapeutics
Also Clin0 DME, Clin0 other eye conditions; 4 undisclosed programs RD/Clin0 IPF, liver fibrosis, myelofibrosis, lung inflammation, neurodegeneration, neuroinflammation, solid tumors
Aviceda Therapeutics is developing glyco-therapeutics that modulate immune system dysfunction. The human glycome is far more diverse than the proteome or genome and plays a role in regulating innate immune checkpoints. Aviceda is using their technology platform to engineer highly optimized glyco-ligands that can modulate the self-recognition receptors on immune cells and convert them to a resolution state. Aviceda’s lead candidate, AVD-103, is being developed to target various immune system responses that contribute to pathology associated with dry age-related macular degeneration. AVD-104 is one of several glyco-immune therapeutics Aviceda is developing that are delivered via biodegradable nanoparticles.
Sr. Director/VP, Biology and Translational Researc...
Belfast, Nothern Ireland|33 days ago
Senior/Principal Scientist, Glycochemistry/Carbohy...
Cambridge, Massachusetts|85 days ago